We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-15.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.41B
AUM Growth
-$2.89B
Cap. Flow
-$1.47B
Cap. Flow %
-27.24%
Top 10 Hldgs %
37.29%
Holding
165
New
19
Increased
15
Reduced
46
Closed
34

Top Buys

Rank Stock Value
1
LOGC
LogicBio Therapeutics, Inc. Common Stock
LOGC
+$78.1M
2
THOR
Synthorx, Inc. Common Stock
THOR
+$77.1M
3
CVS icon
CVS Health
CVS
+$59.3M
4
CELG
Celgene Corp
CELG
+$58.5M
5
GH icon
Guardant Health
GH
+$56.5M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$149M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$98.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$81.7M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81M
5
EW icon
Edwards Lifesciences
EW
+$79.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Financials 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHC icon
26
Bausch Health
BHC
$1.68B
$66.5M 1.23%
3,600,300
+1,696,400
+89% +$40.4M
ARGX icon
27
argenx
ARGX
$55.3B
$62.2M 1.15%
647,600
-71,200
-10% -$6.33M
HUM icon
28
Humana
HUM
$43.8B
$59.2M 1.09%
206,500
-186,500
-47% -$59.1M
GH icon
29
Guardant Health
GH
$19.1B
$57.7M 1.07%
+1,534,464
New +$56.5M
CRNX icon
30
Crinetics Pharmaceuticals
CRNX
$8.88B
$57.4M 1.06%
1,914,282
– –
EXEL icon
31
Exelixis
EXEL
$14.1B
$55.1M 1.02%
2,801,900
– –
PBYI icon
32
Puma Biotechnology
PBYI
$398M
$52.9M 0.98%
2,598,883
-106,298
-4% -$3.19M
PTCT icon
33
PTC Therapeutics
PTCT
$6.2B
$52.2M 0.96%
1,519,700
+244,700
+19% +$8.8M
CVS icon
34
CVS Health
CVS
$138B
$52M 0.96%
+793,800
New +$59.3M
DCPH
35
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$51.3M 0.95%
2,442,200
+488,700
+25% +$12M
A icon
36
Agilent Technologies
A
$39.6B
$50.8M 0.94%
753,000
-332,100
-31% -$22.3M
CLVS
37
DELISTED
Clovis Oncology, Inc.
CLVS
$49.4M 0.91%
2,752,200
+517,630
+23% +$10.6M
IOVA icon
38
Iovance Biotherapeutics
IOVA
$2.04B
$49.1M 0.91%
5,548,326
– –
CNC icon
39
Centene
CNC
$31.1B
$48.1M 0.89%
834,800
+160,000
+24% +$10.7M
UNH icon
40
UnitedHealth
UNH
$387B
$46.5M 0.86%
186,500
– –
EHTH icon
41
eHealth
EHTH
$42.5M
$42.3M 0.78%
1,100,000
-511,200
-32% -$17.2M
ACET icon
42
Adicet Bio
ACET
$76.6M
$41.6M 0.77%
43,128
– –
ZLAB icon
43
Zai Lab
ZLAB
$2.06B
$40.7M 0.75%
1,753,538
– –
BOLD
44
DELISTED
Audentes Therapeutics, Inc
BOLD
$40.4M 0.75%
1,893,500
-286,500
-13% -$7.39M
ONC
45
BeOne Medicines Ltd
ONC
$34B
$39.6M 0.73%
282,500
– –
BLUE
46
DELISTED
bluebird bio
BLUE
$38.4M 0.71%
29,892
-5,558
-16% -$8.53M
HRTX icon
47
Heron Therapeutics
HRTX
$93.6M
$36.3M 0.67%
1,400,300
-114,200
-8% -$3.14M
TNDM icon
48
Tandem Diabetes Care
TNDM
$1.23B
$36M 0.67%
948,000
+233,500
+33% +$8.25M
MOH icon
49
Molina Healthcare
MOH
$10.5B
$35.4M 0.66%
305,000
-183,781
-38% -$24.1M
NBIX icon
50
Neurocrine Biosciences
NBIX
$18.3B
$35.3M 0.65%
494,200
+356,400
+259% +$34.1M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2018 Portfolio in Review

As of Q4 2018, OrbiMed held 165 positions worth $5.41B, down 35% from $8.3B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed withdrew a net $1.47B in Q4 2018, closing 34 positions and reducing 46 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in LogicBio Therapeutics, Inc. Common Stock worth $67.3M.

  • OrbiMed's largest Q4 2018 buy was LogicBio Therapeutics, Inc. Common Stock: 6,466,783 shares worth $67.3M.
  • OrbiMed added most to Celgene Corp in Q4 2018, an estimated $58.5M increase.
  • OrbiMed's biggest Q4 2018 reduction was Alexion Pharmaceuticals, cutting an estimated $98.5M.
  • OrbiMed fully exited Jazz Pharmaceuticals in Q4 2018, selling an estimated $149M.
  • OrbiMed's ten largest holdings make up 37% of its $5.41B portfolio in Q4 2018.
  • OrbiMed opened 19 new positions and closed 34 in Q4 2018.
  • OrbiMed's portfolio value fell 35% quarter-over-quarter to $5.41B.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.